We conducted a 9-cM genome scan in a large bipolar pedigree sample from the National Institute of Mental Health genetics initiative (1060 individuals from 154 multiplex families). We performed parametric and nonparametric analyses using both standard diagnostic models and comorbid conditions thought to identify phenotypic subtypes: psychosis, suicidal behavior, and panic disorder. Our strongest linkage signals (genome-wide significance) were observed on chromosomes 10q25, 10p12, 16q24, 16p13, and 16p12 using standard diagnostic models, and on 6q25 (suicidal behavior), 7q21 (panic disorder) and 16p12 (psychosis) using phenotypic subtypes. Several other regions were suggestive of linkage, including 1p13 (psychosis), 1p21 (psychosis), 1q44, 2q24 (suicidal behavior), 2p25 (psychosis), 4p16 (psychosis, suicidal behavior), 5p15, 6p25 (psychosis), 8p22 (psychosis), 8q24, 10q21, 10q25 (suicidal behavior), 10p11 (psychosis), 13q32 and 19p13 (psychosis). Over half the implicated regions were identified using phenotypic subtypes. Several regions -1p, 1q, 6q, 8p, 13q and 16p -have been previously reported to be linked to bipolar disorder. Our results suggest that dissection of the disease phenotype can enrich the harvest of linkage signals and expedite the search for susceptibility genes. This is the first large-scale linkage scan of bipolar disorder to analyze simultaneously bipolar disorder, psychosis, suicidal behavior, and panic disorder.
Introduction
Bipolar disorder (BP) is a common mental illness afflicting about 1% of the population worldwide. It is characterized by severe disturbances of mood such as depression and mania. BP constitutes a major public health concern due to high rates of hospitalizations, psychosocial impairment, substance abuse, and suicide. Family, twin, and adoption studies support a substantial genetic component for BP. 1 Linkage studies, including genome-wide scans, have implicated multiple chromosomal regions as possible sites for susceptibility loci. However, inconsistent results underscore the challenge in attaining compelling findings. 2, 3 The conflicting results have been attributed to genetic and phenotypic heterogeneity, leading to reduced statistical power and increased rates of both false-positive and false-negative findings. To redress this problem, the National Institute of Mental Health (NIMH) has launched a Genetics Initiative to collect large pedigree samples with detailed diagnostic data. Such samples might prove more informative and statistically powerful than smaller individual studies. The latest efforts in this undertaking, aimed at augmenting previous, more limited family collections, are two multicenter collaborative projects. The results of the first study, coordinated at Indiana University and consisting of 1152 individuals from 250 mostly nuclear families, were recently published. 4 The second study, coordinated at Columbia University and comprised of 1060 individuals from 154 nuclear and extended pedigrees, is described in the present paper. The present sample is completely independent of previously published samples.
Unlike the previously published NIMH-initiated studies, which largely employed standard diagnostic models of BP, the present study also utilized phenotypic subtypes identified by psychosis, suicidal behavior, and panic disorder. Dissection of the disease phenotype in complex disorders has been shown to reduce heterogeneity, thereby enhancing the resolution of linkage analysis (e.g., Alzheimer's disease, diabetes mellitus, and breast cancer). We hypothesized that a similar pattern may be observed in BP. We report multiple chromosomal sites with lod scores supportive of linkage, including regions with no prior evidence of linkage. As hypothesized, a substantial number of linkage signals were obtained using phenotypic subtypes of BP.
Materials and methods

Subjects
Our research protocol, including ascertainment and diagnostic procedures, is described in detail elsewhere (NIMH Center for Collaborative Genetic Studies of Mental Disorders, http://zork.wustl.edu/ nimh). In brief, multiplex pedigrees with BP were ascertained at two sites: Columbia University Medical Center, New York, and Hadassah-Hebrew University Medical Center, Jerusalem. The same protocol was used at both sites. Participants were asked to give informed consent for interview, a blood sample for DNA and cell lines, and permission to contact relatives. The institutional review boards at each participating site approved the study. The overall sample consisted of 1060 individuals (age 16 and over) in 154 families, including 91 nuclear families and 63 extended pedigrees. The bulk of the sample was obtained in the US (942 individuals in 134 families). The major ethnic category (94% of the sample) consisted of Whites of European ancestry (42% West Europeans, 26% Anglo-Saxons, 12% East Europeans, 10% North Europeans, and 4% South Europeans). The remainder (6% of the sample) was comprised of Puerto Ricans/Mexicans, Native Americans, Asians, Arabs and Asians. There was negligible ethnic admixture within families ( < 1%).
Families were identified by screening admissions at local psychiatric facilities or by advertisements through mental health advocacy and support groups, Web sites, and professional organizations. Pedigrees were accepted into the study when a proband with bipolar I disorder (BPI; mania and major depression) had at least one first-degree relative with a lifetime history of mania: BPI or schizoaffective disorder, bipolar type (SABP) (the BPI category comprised over 90% of manic syndromes in this sample). Families with bilineal matings (both parents affected with BPI or SABP) were not included. Whenever possible, additional relatives, in both the immediate and extended family, were included if they had either BPI, SABP, bipolar II disorder (BPII; hypomania and major depression), or major depressive disorder, recurrent (MDDR). These disorders are considered part of the BP 'spectrum' by virtue of their aggregation in families of bipolar probands.
The clinical evaluation was based on personal interviews using the Diagnostic Interview for Genetic Studies (DIGS) 5 and supplemented by the Family Instrument for Genetic Studies (FIGS) and medical records. The DIGS is a polydiagnostic instrument for the assessment of mood disorders and related conditions. It displays high test-retest reliability for the disorders of interest. 5 The FIGS is used to obtain diagnostic information on relatives. Interviewers had extensive clinical experience and undertook on-site training in the use of these instruments. Best estimate consensus diagnoses were made by independent diagnosticians using all available sources of information. Diagnostic determinations were based on the Diagnostic Manual for Mental Disorders, Fourth Edition (DSM-IV) and were made blind to familial relationships, clinical status of other relatives, and genotypic information. Diagnostic reliability was high for all BP 'spectrum' disorders of interest (k coefficients: 0.93, 0.94, and 0.94 for manic syndromes, BPII, and MDDR, respectively).
We used several affection status definitions, including the three standard diagnostic models commonly used in linkage studies of BP: BP1 (manic syndromes, mostly BPI), BP2 (same as BP1 plus BPII), and BP3 (same as BP2 plus MDDR). Using these models, the disease phenotype is progressively broadened from narrow (i.e., BP1) to broader phenotypic boundaries. In an attempt to further refine the disease definition, we classified the affected phenotype using three commonly observed comorbid conditions: psychosis (delusions and/or hallucinations in the manic and/or depressive phase), suicidal behavior, and panic disorder. This resulted in several additional phenotypes: BP-P1, BP-P2, and BP-P3 (BP with psychosis; corresponding to BP1, BP2, and BP3, respectively; detailed description in Park et al. 6 ), psychotic-manic (psychotic while manic), psychoticdepressed (psychotic only while depressed), BP (all affected) with suicidal behavior (all attempts vs lethal outcome), and BP (all affected) with panic disorder. The distribution of diagnoses and the number of affected individuals in each phenotypic category are shown in Table 1 .
Genotyping
Genotyping was carried out at the NIH Center for Inherited Disease Research (CIDR), as described (www.cidr.jhmi.edu). In brief, the protocol consisted of automated fluorescent microsatellite analysis. PCR products were separated and detected on an ABI 3700 Sequencer. The marker set includes 391 markers, with average spacing of B9 cM and average marker heterozygosity of 0.76. The cumulative error rate based on all paired genotypes was 0.07%. All genotyping was performed blind to clinical status and family relationship.
We checked for Mendelian inconsistencies in marker data using the Pedcheck program. 7 Ambiguous marker genotypes were deleted prior to linkage analysis. Allele frequencies were estimated from all genotyped individuals using the Gconvert program (http://www2.qimr.edu.au/davidD).
Statistical analysis
Two-point and multipoint parametric analyses were carried out using the MLINK program from the FASTLINK package, 8 producing two-point lod scores (LOD's) and multipoint lod scores (MLOD's), respectively. Since the mode of inheritance is unknown, we tested both dominant and recessive transmissions. We employed genetic parameters commonly used in similar analyses of BP: dominant model, disease allele frequency of 0.01 and a penetrance of 80% for gene carriers and 0.01% for noncarriers; recessive transmission, the same penetrance in gene carriers and noncarriers but a disease allele frequency of 0.10. We also obtained LOD's under linkage heterogeneity (HLOD's) and multipoint nonparametric results using GENEHUNTER (version 2.1). 9 The nonparametric linkage statistic (NPL), a measure of identity-by-descent sharing of alleles among affected individuals, was calculated as described. 10 To reduce the impact of nonpenetrant disease alleles on the analysis, all unaffected individuals were coded as unknown.
To gauge the empirical genome-wide significance of our results, we used genotypic information and marker allele frequencies from our data, and simulated data sets under the assumption of no linkage, using the program SIMULATE 11 with 1000 replicates. We used BP with suicidal behavior (all attempts) as the phenotype because this phenotype (as well as panic disorder) reached the highest two-point LOD scores (Table 2) , and because the linked region also showed linkage (to BP2) with NPL analysis (Table 4) . We employed Lander and Kruglyak's 12 approach to defining significance of linkage using the rates of chance occurrence: suggestive (once in a genome scan); significant (once in 20 scans, or P < 0.05), highly significant (once in 100 scans, or P < 0.01).
Results
For two-point parametric analysis, our simulation analysis yielded LOD thresholds of 1.83, 2.83, and 3.43 for suggestive, significant, and highly significant linkage, respectively. The corresponding HLOD thresholds were 1.18, 1.98, and 2.75, and the NPL thresholds were 1.63, 2.10, and 2.37. These thresholds are lower than those proposed by Lander and Kruglyak 12 (e.g., 1.9 and 3.3 for suggestive and significant linkage, respectively, using two-point parametric analysis). However, their simulations were based on 100 sib-pairs with an infinitely dense genetic map, whereas we utilized our own pedigrees and genotypic data.
Our linkage results are shown in Tables 2-4. Tables  2 and 3 show parametric LOD and HLOD results, respectively. Table 4 displays NPL results. Included are all loci with suggestive, significant, or highly significant genome-wide linkage.
A graphical display of HLOD and NPL results is shown in Figures 1 and 2 , respectively.
Based on our simulation results, four loci showed evidence of highly significant linkage (genome-wide P < 0.01): D7S2212 at 7q21.1 (HLOD = 2.85, panic disorder; Table 3 ), D10S1237 at 10q25.3 (NPL = 2.50, BP2; Table 4 ), D16S2616 at 16p13.3 (NPL = 2.65, BP2; Table 4 ), and D16S3103 at 16p12.3 (NPL = 2.73, PB2; Table 4 ). Four other loci supported significant l inkage (genome-wide P < 0.05): D6S2436 at 6q25.2 (HLOD = 2.37, suicide-lethal; Table 3 ), D16S3103 at 16p12.3 (HLOD = 2.13, BP-P3; Table 3 ), D10S1243 at 10p12.3 (NPL = 2.16, BP1; Table 4 ) and D16S2621 at 16q24.2 (NPL = 2.29, BP3; Table 4 ). In all, 15 loci showed evidence for suggestive linkage (see Tables) . These results should be viewed in the context of potential multiple tests effects (see Discussion).
The MLOD's (same models as in the two-point parametric analysis; Table 2 ) were generally supportive of the two-point results. Although multipoint parametric analysis of complex traits tends to yield deflated lod scores, 13 about half the loci showed increased lod scores. HLOD's corresponding to the two-point parametric results reached significant or highly significant values at three loci, with alpha (fraction of linked families) ranging from 0.37 to 0.58 (Table 3) . Table 5 summarizes linkage signals by disease phenotype. These occurred at 13 loci using standard diagnostic models, and at 15 loci using phenotypic subtypes (psychosis, nine loci; suicidal behavior, five loci; panic disorder, one locus). Four loci gave Included are HLOD scores that met our simulation-based criteria for genome-wide highly significant, significant, or suggestive linkage (see Results). Significant (P < 0.05) and highly significant (P < 0.01) values are in bold. Numbers in parentheses, alpha. Included are NPL scores that met our simulation-based criteria for genome-wide highly significant, significant or suggestive linkage (see Results). Significant (P < 0.05) and highly significant (P < 0.01) values are in bold.
evidence of linkage with more than one disease phenotype: D2S1353 at 2q24.1 (BP3, suicidal-lethal), D4S2366 at 4p16.1 (BP-P1, suicide-lethal), D6S2436 at 6q25.2 (BP3. Suicide-lethal), and D16S3103 at 16p12.3 (BP2, BP-P3). Thus, the 'net' number of linked loci (any disease phenotype) is 23.
Discussion
We conducted a genome-wide scan in a new, sizable sample of families from the NIMH Genetics Initiative for BP. To our knowledge, this is the first large-scale linkage study to analyze simultaneously phenotypic subtypes of BP identified by psychosis, suicidal behavior, and panic disorder. In complex disorders such as BP, phenotypic subtypes likely augment the resolution of linkage analysis and enhance the detection of susceptibility loci. We identified over 20 sites of interest. Our strongest linkage signals (genome-wide significance) were observed on 6q25, 7q21, 10p12, 10q25, 16p13, 16p12, and 16q24. Only five regions showed support for linkage under both parametric and nonparametric analyses. This speaks to the potential merit in utilizing several analytical approaches in complex traits such as BP, to maximize detection of linkage.
As we hypothesized, a substantial proportion of our linkage signals (over half) occurred with phenotypic subtypes of BP, in particular psychosis and suicidal behavior. Psychosis and suicidal behavior signify severity of the clinical phenotype and may therefore possess a stronger genetic component than standard disease definitions. Only three regions showed linkage signals with both standard disease definitions and phenotypic subtypes -2q24 (BP3, suicidal behavior), 10q25 (BP2, suicidal behavior), and 16p12 (BP2, psychosis). Also, with exception of one region -4p16 (psychosis, suicidal behavior) -there was no overlap among phenotypic subtypes with respect to linkage signals on specific chromosomal regions. This suggests some specificity in genetic susceptibility to disease phenotypes. Also of interest is the observation that further phenotypic refinement, Table 3 .
Genome scan of bipolar disorder R Cheng et al specifically variants of psychosis (manic vs depressed; BP-P1 vs BP-P2 and BP-P3) and suicidal behavior (all attempts vs lethal outcome), enriched the yield of linkage signals. In the case of suicidal behavior, four of the five implicated regions showed linkage to completed suicide (i.e., lethal outcome), suggesting that the most severe form of this phenotype has a stronger genetic substrate than the milder phenotype (i.e., nonlethal suicide attempts). Four regions -1p13, 6p25, 16q24 and 19p13 -appear to be novel; namely, no appreciable linkage in previous linkage studies of BP. Some of the regions implicated in our study overlap with and furnish support for previously reported findings. For example, using an independent sample, we recently reported linkage between BP with psychosis and the 8p22 region. 6 Interestingly, this region is implicated in linkage studies of schizophrenia, a disorder with prominent psychotic features (review and meta-analysis in Lewis et al. 14 ) . Three other regions reportedly linked to schizophrenia 14 -1p, 6p, and 16p -showed evidence of linkage to BP with psychosis in the present study. In another study, 15 region 16p displayed linkage to a common BP-schizophrenia phenotype in families segregating both disorders. There was no evidence of linkage in our sample between psychosis and either 6q24, 13q31-32 or 22q12, regions reported linked to both schizophrenia and BP, 16, 17 or BP in families with psychosis. 18 However, we did observe linkage to 13q32 in our previous study of BP and psychosis, 6 as well as in the present sample though under other disease definitions.
These findings raise the possibility, mentioned by others, 15, 16, 18, 19 and us, 2, 6, 20 that a genetic link may exist between BP and schizophrenia. Of interest in this regard is the reported association between two candidate genes, Neuregulin 1 (NRG1) on 8p22, and Table 4 .
Genome scan of bipolar disorder R Cheng et al G72/G30 on 13q31-32, and both BP and schizophrenia. 21, 22 However, there are uncertainties in the interpretation of these findings. For example, because most of the short arm of chromosome 8 (not just 8p22) has been implicated in schizophrenia by linkage studies, it is not clear if the same loci are involved in the two disorders.
Secondly, the markers reported are too far apart to be mapping a single BP gene at G72/G30. Also, the markers found to be associated with schizophrenia showed no significant allelic association with BP at NRG1. Although haplotypic association was reported, such associations may be false positive in the absence of single marker allelic association due to genotyping errors. Further study is needed to pinpoint common loci for BP and schizophrenia.
There are scant linkage data for suicide in conjunction with psychiatric disorders, BP in particular (review in Zubenko et al.
23
). There is evidence of linkage for suicidal behavior in early-onset major depression, on 2p12, 5q31-33, 6q12, 8p22-21, 11q25, and Xq25-26. 23 However, none of these regions overlaps with the linkage peaks for BP and suicide in our study. Interestingly, however, region 8p shows linkage to BP and psychosis in our sample, raising the possibility that this region harbors genes that affect the expression of both suicidal behavior in early onset major depression and BP with psychosis (as well as schizophrenia; see above). There are numerous association studies of suicidal behavior, independently of specific psychiatric disorders, using candidate genes for tryptophan hydroxylase (TPH1), serotonin transporter (SERT), and various serotonin receptors (HTR). Positive trends notwithstanding, the overall results are inconsistent and largely negative (review in Anduelova et al.; 24 Baldessarini and Included are the strongest linkage signals (Tables 2-4) that met our simulation-based criteria for genome-wide highly significant, significant, or suggestive linkage. Significant (P < 0.05) and highly (P < 0.01) values are in bold.
Hennen 25
). None of these candidate genes resides on regions that showed support for linkage in the present study.
Several regions have been implicated in linkage studies of panic disorder, though no linkage data are available for BP with panic disorder (review in Hamilton et al. 26 ). None of the implicated regions overlaps with the linkage peak for BP with panic disorder in our sample (region 7q21). However, linkage signals in three regions -10q, 27 13q 26 and 16p 26 -were in the general vicinity of linkage peaks for other BP phenotypes in our study: BP2 and BP with suicidal behavior (region 10q), BP1 (region 13q) and BP2 (region 16p). This raises the possibility of some genetic overlap between BP and panic disorder, although the nature of the relationship is not clear. The comorbidity of BP and panic disorder presents another uncertainty. Namely, panic states may be part of the BP spectrum rather than a 'true' form of panic disorder.
As mentioned, most linkage scans of BP employed standard disease definitions. Conflicting results notwithstanding, evidence from individual studies and meta-analyses favors several chromosomal regions as potential sites for susceptibility loci (review in Baron, 2 Segurado et al., 3 Dick et al., 4 Craddock et al.
28
). These include 1p-q, 2q, 2p, 3q, 4p, 4q, 5p, 6q, 7q, 8p-q, 9p-q, 10p-q, 12p-q, 13q, 14q, 16p, 18p-q, 19q, 20p, 21q, and 22q. Some of these regions -in particular, 1p, 2q, 2p, 6q, 7q, 8q, 10q, 13q, and 16p -show some overlap with the regions implicated in the present study. However, since most of our linkage signals were obtained with phenotypic subtypes (as opposed to standard phenotype definitions), a comparison between the present results and previous findings is not straightforward. It would be interesting to determine if a reanalysis of other linkage scans, using phenotypic subtypes, would show significant overlap with the present findings.
Statistically significant linkage heterogeneity (parametric analysis) was obtained for three regions, with three other regions showing suggestive evidence. The fraction of linked families ranged from about 40 to 60%, suggesting a common genetic factor. Given the likely heterogeneous nature of BP, we do not suggest that failure to reject the null hypothesis for other loci implies that it should be accepted. The small size of the Israeli sample ( < 15% of the total sample) did not allow a meaningful comparison with US pedigrees with respect to linkage results. However, an independent sample obtained in the US and Israel showed a similar pattern of results in the two populations. 6, 29 Larger samples are required to assess heterogeneity and differences in linkage findings among populations and ethnic groups.
Our findings must be viewed in light of several limitations. First, although some of the regions presumed linked in our sample converge or overlap with findings reported previously, the regions in the different studies are sizable and their boundaries are not well defined. Also, other loci implicated in BP show no evidence of linkage in this study. The variability in linkage results may be partly explained by the complexity of BP. A confounding factor is the diversity among studies in study populations, ascertainment and diagnostic criteria, marker coverage, analytic methods, and sample size (influencing power to detect linkage). Simulation studies of complex disorders have shown considerable variability in the estimated location of susceptibility loci. 30 Additionally, replication of true linkage in subsequent samples is substantially more difficult. 31 Second, we used a number of diagnostic and genetic models. Though a common practice in genetic analysis of complex disorders, this could lead to inflated linkage signals due to multiple testing. Namely, the statistical significance of our findings, though based on empirical P-values obtained by simulation, should be viewed accordingly. However, the fact that many of these models are correlated (e.g., diagnostic models such as BP1, BP2, and BP3, or BP-P1 through P3, are nested within each other) partially obviates this problem. Also, the various phenotype definitions are not arbitrary, as they are based on clinical evidence and observations from family studies. There is no clear-cut, obvious method to adjust for multiple testing in these circumstances. Third, a clearer pattern of linkage results might ensue with further refinement of the phenotype. For example, inclusion of phenotypic variants such as psychosis with suicidal behavior (vs psychosis with no such behavior), panic disorder in BP1 (vs BP2 and BP3), as well as other possible comparisons. We did not include such permutations in the present analyses because this could further compound multiple testing. Fourth, as mentioned earlier, our observation that BP is linked to regions implicated in other disorders such as schizophrenia and panic disorder does not prove that these disorders have genes in common. As psychosis, suicide and panic disorder are all phenotypes that are part of the BP spectrum, linkage findings for these phenotypes need not be taken as evidence that they are relevant for these conditions independently of BP. Until the genes themselves are identified and characterized, this remains a mere hypothesis. Notwithstanding these limitations, supporting evidence from other studies for some of our results, and the strength of linkage signals compared to other regions in our genome scan, offer a measure of confidence. Further study is needed to extend and confirm these findings.
In summary, this study reports genome scan results for the latest pedigree sample from the NIMH genetics initiative for BP. Our sample is one of the largest collected to date, with increased power to detect loci of small effect. Also, the analysis of several phenotypic subtypes simultaneously, in a sample of this magnitude, is a novelty that yielded multiple linkage signals of potential relevance for BP and other psychiatric conditions such as schizophrenia, suicidal behavior, and panic disorder.
